Monoamine Oxidase Deficiency (MAOD) Market Outlook

Thelansis’s “Monoamine Oxidase Deficiency (MAOD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Monoamine Oxidase Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Monoamine Oxidase Deficiency (MAOD) Overview

Monoamine oxidase deficiency (MAOD), most commonly referring to monoamine oxidase A deficiency or Brunner syndrome, is a rare X-linked recessive neurodevelopmental disorder caused by loss-of-function mutations in the MAOA gene, encoding an enzyme responsible for degrading serotonin, dopamine, and norepinephrine, resulting in pathological accumulation of these monoamine neurotransmitters within the central nervous system. The resulting neurochemical dysregulation disrupts normal neurodevelopmental processes and impulse control circuitry, predominantly affecting males given X-linked inheritance, while heterozygous female carriers typically remain unaffected or exhibit milder phenotypic expression. Affected individuals present with mild to moderate intellectual disability, impulsive and disproportionately aggressive behaviour often triggered by frustration or stress, sleep disturbances, and in some cases autonomic abnormalities including abnormal sweating patterns. Diagnosis integrates clinical and behavioural phenotyping, biochemical assessment demonstrating elevated urinary monoamine metabolites, and confirmatory MAOA gene sequencing. No disease-modifying or curative therapy currently exists; management is supportive and behaviourally oriented, encompassing structured behavioural interventions, psychoeducation, and cautious pharmacological management of impulsivity and aggression, alongside mood stabilisers in selected cases. Genetic counselling addressing X-linked inheritance pattern and carrier risk is essential for affected families. Prognosis varies considerably with behavioural severity and access to structured support; multidisciplinary developmental, psychiatric, and genetic counselling involvement is integral to long-term patient and family-centred management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)